Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
6.70
-0.08 (-1.18%)
Aug 26, 2026, 12:45 PM EDT - Market open
Valneva SE Revenue
Valneva SE had revenue of 34.94M EUR in the quarter ending June 30, 2026, a decrease of -27.71%. This brings the company's revenue in the last twelve months to 142.94M, down -27.19% year-over-year. In the year 2025, Valneva SE had annual revenue of 174.66M with 3.00% growth.
Revenue (ttm)
142.94M EUR
Revenue Growth
-27.19%
P/S Ratio
3.84
Revenue / Employee
230,544 EUR
Employees
620
Market Cap
627.52M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| MiMedx Group | 355.17M |
| Arvinas | 316.70M |
| Autolus Therapeutics | 117.39M |
| Verastem | 87.53M |
| Scribe Therapeutics | 36.28M |
| Prime Medicine | 4.07M |
| Entera Bio | 42.00K |
VALN News
- 10 days ago - Pfizer, Valneva announce EMA validation for PF-07307405 MAA - TheFly
- 12 days ago - Valneva Stock (VLN) Soars Over 20% On Lyme Disease Vaccine Hopes - TipRanks
- 12 days ago - Pfizer And Valneva's Lyme Vaccine Clears EMA Review Gate - Nasdaq
- 12 days ago - Pfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA - Nasdaq
- 12 days ago - Pfizer Inc.: Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Finanz Nachrichten
- 12 days ago - Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - GlobeNewsWire
- 12 days ago - Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Wallstreet:Online
- 12 days ago - Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Business Wire